Public Profile

Formycon AG

Formycon AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its expertise in the development of biosimilars. Founded in 2002, the company has established a strong presence in Europe and beyond, focusing on innovative therapies that enhance patient care. With a commitment to quality and efficacy, Formycon AG offers a range of biosimilar products that stand out for their rigorous development processes and regulatory compliance. The company has achieved significant milestones, including successful partnerships and product launches that underscore its position in the competitive biopharmaceutical landscape. Recognised for its scientific excellence, Formycon AG continues to drive advancements in the industry, making substantial contributions to the accessibility of biologic treatments for patients worldwide.

DitchCarbon Score

How does Formycon AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

15

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Formycon AG's score of 15 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.

80%

Formycon AG's reported carbon emissions

Formycon AG, headquartered in Germany, currently does not have publicly available carbon emissions data or specific reduction targets. As a company in the biopharmaceutical sector, Formycon is likely aware of the growing importance of climate commitments and may be exploring initiatives to address carbon emissions. However, without concrete figures or defined targets, it is challenging to assess their current climate impact or future commitments. The industry context suggests that many companies are increasingly adopting science-based targets and sustainability practices to mitigate their environmental footprint.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Formycon AG's primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Formycon AG is headquartered in DE, which has a rank of medium, indicating medium grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Formycon AG is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Pfizer

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 6 days ago

Amgen

US
Chemicals nec
Updated 7 days ago

Regeneron

US
Research and development services (73)
Updated 7 days ago

Samsungbioepis Co,.Ltd

KR
Research and development services (73)
Updated 7 days ago

Fresenius

DE
Medical, precision and optical instruments, watches and clocks (33)
Updated 5 days ago

Xbrane Biopharma AB

SE
Education services (80)
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers